And why on earth would you say that? You are a very fickle person my friend.
On March 17, 2011, the Company signed an agreement with The Unconventional Foundation for Autism (UF4A) to develop treatment plans and targeted cannabis-based medicine for the treatment of autism. In conjunction with the partnership, the Company’s president and CEO, Robert Melamede, Ph.D. will join the board of UF4A and work alongside their staff to document and provide scientific guidance on the 10 autism treatment with medical marijuana case studies that UF4A is currently involved with.
The Company anticipates having to raise additional capital to fund operations over the next 12 months. To the extent that it is required to raise additional funds to acquire properties, and to cover costs of operations, the Company intends to do so through additional public or private offerings of debt or equity securities.